atezolizumab,cabozantinib
exelixis,roche
['cosmic-021', 'sclc', 'nsclc']
i hope you were able to catch sci member at as he presented an update on the cosmic-021 trial for #nsclc patients who do not have the option of a targeted tx due to their genetic alterations. #asco22 
Stanford University medical oncologist and cancer scientist, and Director of the Stanford Cancer Institute.  Follows and retweets are not endorsements.